SIRT1 Catalytic Activity Has Little Effect on Tumor Formation and Metastases in a Mouse Model of Breast Cancer

The protein deacetylase SIRT1 has been implicated in the regulation of a large number of cellular processes that are thought to be required for cancer initiation and progression. There are conflicting data that make it unclear whether Sirt1 functions as an oncogene or tumor suppressor. To assess the effect of SIRT1 on the emergence and progression of mammary tumors, we crossed mice that harbor a point mutation that abolishes SIRT1 catalytic activity with mice carrying the polyoma middle T transgene driven by the murine mammary tumor virus promoter (MMTV-PyMT). The absence of SIRT1 catalytic activity neither accelerated nor blocked the formation of tumors and metastases in this model. There was a lag in tumor latency that modestly extended survival in Sirt1 mutant mice that we attribute to a delay in mammary gland development and not to a direct effect of SIRT1 on carcinogenesis. These results are consistent with previous evidence suggesting that Sirt1 is not a tumor promoter or a tumor suppressor.

[1]  M. Roth,et al.  Sorting out functions of sirtuins in cancer , 2014, Oncogene.

[2]  M. McBurney,et al.  Sirt1-deficient mice exhibit an altered cartilage phenotype. , 2013, Joint, bone, spine : revue du rhumatisme.

[3]  D. Herranz,et al.  SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency , 2013, Oncogene.

[4]  L. Guarente,et al.  SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. , 2013, Cell reports.

[5]  M. McBurney,et al.  SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress. , 2013, Genes & cancer.

[6]  B. Morris.  Seven sirtuins for seven deadly diseases of aging. , 2013, Free radical biology & medicine.

[7]  D. Faller,et al.  SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. , 2013, The Journal of endocrinology.

[8]  Laisheng Li,et al.  MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1 , 2013, Clinical and Experimental Medicine.

[9]  A. Bild,et al.  SIRT1 pathway dysregulation in the smoke-exposed airway epithelium and lung tumor tissue. , 2012, Cancer research.

[10]  Weihua Jia,et al.  Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer , 2012, Medical Oncology.

[11]  H. Sakurai,et al.  SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. , 2012, Oncology reports.

[12]  S. Paik,et al.  Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma , 2012, Journal of Clinical Pathology.

[13]  S. Costantini,et al.  Interactomic and Pharmacological Insights on Human Sirt-1 , 2012, Front. Pharmacol..

[14]  R. Weindruch,et al.  The caloric restriction paradigm: Implications for healthy human aging , 2012, American journal of human biology : the official journal of the Human Biology Council.

[15]  K. Boekelheide,et al.  SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  V. Ganapathy,et al.  SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. , 2011, Cancer research.

[17]  J. Stingl.  Estrogen and Progesterone in Normal Mammary Gland Development and in Cancer , 2011, Hormones & cancer.

[18]  Byoung Kil Lee,et al.  Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. , 2011, Human pathology.

[19]  Ji-Seon Lee,et al.  Negative regulation of stress‐induced matrix metalloproteinase‐9 by Sirt1 in skin tissue , 2010, Experimental dermatology.

[20]  Junjie Chen,et al.  Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. , 2010, Molecular cell.

[21]  B. Tang.  Sirt1 and cell migration , 2010, Cell adhesion & migration.

[22]  N. Davidson,et al.  Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. , 2010, Carcinogenesis.

[23]  M. McBurney,et al.  SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol , 2009, Oncogene.

[24]  K. Jang,et al.  Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma , 2009, Clinical Cancer Research.

[25]  Z. Lou,et al.  A c-Myc–SIRT1 feedback loop regulates cell growth and transformation , 2009, The Journal of cell biology.

[26]  V. Longo.  Linking sirtuins, IGF-I signaling, and starvation , 2009, Experimental Gerontology.

[27]  W. Gu,et al.  How does SIRT1 affect metabolism, senescence and cancer? , 2009, Nature Reviews Cancer.

[28]  F. Alt,et al.  SIRT1 Redistribution on Chromatin Promotes Genomic Stability but Alters Gene Expression during Aging , 2008, Cell.

[29]  C. Deng,et al.  Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. , 2008, Molecular cell.

[30]  X. Wang,et al.  Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. , 2008, Cancer cell.

[31]  W. Hahn,et al.  The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth , 2008, PloS one.

[32]  M. McBurney,et al.  SirT1 Regulates Energy Metabolism and Response to Caloric Restriction in Mice , 2008, PloS one.

[33]  J. Qin,et al.  Negative regulation of the deacetylase SIRT1 by DBC1 , 2008, Nature.

[34]  Junjie Chen,et al.  DBC1 is a negative regulator of SIRT1 , 2008, Nature.

[35]  M. Salto‐Tellez,et al.  Function of the SIRT1 protein deacetylase in cancer. , 2007, Biotechnology journal.

[36]  J. Weber,et al.  Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. , 2007, The Biochemical journal.

[37]  T. Nagy,et al.  SIRT1 is significantly elevated in mouse and human prostate cancer. , 2007, Cancer research.

[38]  S. Wang,et al.  SIRT1 interacts with p73 and suppresses p73‐dependent transcriptional activity , 2007, Journal of cellular physiology.

[39]  C. Ware,et al.  SirT1 modulates the estrogen–insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice , 2007, Breast Cancer Research.

[40]  S. Baylin,et al.  Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses , 2005, Cell.

[41]  B. Rogina,et al.  Sir2 mediates longevity in the fly through a pathway related to calorie restriction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[43]  C. Dabrosin,et al.  Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants , 2003, Breast Cancer Research and Treatment.

[44]  K. Korach,et al.  Mammary Gland Development and Tumorigenesis in Estrogen Receptor Knockout Mice , 1997, Journal of Mammary Gland Biology and Neoplasia.

[45]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[46]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[47]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[48]  L. Guarente,et al.  Negative control of p53 by Sir2alpha promotes cell survival under stress. , 2001, Cell.

[49]  P. Defossez,et al.  Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. , 2000, Science.

[50]  B. Nielsen,et al.  Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice , 1998, Oncogene.

[51]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.